Table 1.

Response rate and prevalence of PRKDC mutations in data cohorts from several clinical cohorts [69]

Paper	Cancer	Sample size	Sample with PRKDC mutation	Responder with PRKDC	Response rate (%)
Synder et al.	Melanoma	64	2 (3.1%)	2	100
Rizvi et al.	NSCLC	31	3 (9.7%)	2	66.70
Van Allen et al.	Melanoma	110	9 (8.2%)	4	55.60
Anagnostou et al.	NSCLC	4	1 (25%)	1	100
Maio et al.	Renal cell carcinoma	98	2 (2.0%)	1	50
Riaz et al.	Melanoma	65	2 (3.1%)	1	50